Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Evidence signal Provider-reviewed bundle 8 source-backed citations are connected to this page
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
without trisegmentectomy or lobe split 47144 with trisegment split of whole liver graft into 2 partial liver grafts (ie
Systemic tissue support
US$ 22.03
US$ 27.36
US$ 23.17
US$ 21.87
US$ 23.81
US$ 27.93
US$ 22.25
